Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD cut its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 33.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,016,028 shares of the company's stock after selling 520,915 shares during the period. Cellebrite DI comprises approximately 1.8% of Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD's portfolio, making the stock its 18th largest position. Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD owned 0.49% of Cellebrite DI worth $22,365,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the business. True Wind Capital Management L.P. boosted its position in Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock worth $305,358,000 after buying an additional 2,130,386 shares during the period. FMR LLC boosted its position in Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company's stock worth $94,586,000 after buying an additional 3,239,307 shares during the period. Pembroke Management LTD lifted its position in shares of Cellebrite DI by 4.4% in the 4th quarter. Pembroke Management LTD now owns 1,992,432 shares of the company's stock worth $43,893,000 after purchasing an additional 84,087 shares during the period. Principal Financial Group Inc. acquired a new position in shares of Cellebrite DI in the 3rd quarter worth approximately $23,402,000. Finally, Two Sigma Advisers LP lifted its position in shares of Cellebrite DI by 9.8% in the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company's stock worth $22,584,000 after purchasing an additional 120,000 shares during the period. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on CLBT shares. Lake Street Capital boosted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Finally, Needham & Company LLC restated a "buy" rating and issued a $28.00 price target on shares of Cellebrite DI in a research report on Monday. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $23.43.
Read Our Latest Stock Analysis on CLBT
Cellebrite DI Stock Up 2.7 %
NASDAQ:CLBT opened at $17.23 on Wednesday. The company has a fifty day moving average of $21.67 and a 200-day moving average of $19.72. The firm has a market capitalization of $3.55 billion, a P/E ratio of -12.40, a P/E/G ratio of 4.27 and a beta of 1.53. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
